---
title: "688382.SH (688382.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688382.SH/news.md"
symbol: "688382.SH"
name: "688382.SH"
parent: "https://longbridge.com/en/quote/688382.SH.md"
datetime: "2026-03-13T22:20:36.664Z"
locales:
  - [en](https://longbridge.com/en/quote/688382.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688382.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688382.SH/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688382.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688382.SH/news.md)


# 688382.SH (688382.SH) — Related News

### [After losing 1.3 billion yuan in four years, InventisBio is trapped in a "vicious cycle": the drugs have been sold, but the money hasn't been received](https://longbridge.com/en/news/278245544.md)
*2026-03-08T11:24:14.000Z*
> InventisBio (688382) delivered concerning performance in 2025, with annual revenue of only 37.3253 million yuan, a year-

### [Xianwei Biologics: The world's first biased GLP-1 weight loss drug, Xianwei Ying, has been approved for market launch](https://longbridge.com/en/news/278033359.md)
*2026-03-06T06:06:09.000Z*
> First, for Dazheng Biotechnology announced: The world's first cAMP biased GLP-1 receptor agonist, Enoglutide injection (

### [InventisBio: Expected net loss of 317 million yuan for the fiscal year 2025](https://longbridge.com/en/news/277022207.md)
*2026-02-26T10:11:31.000Z*
> InventisBio announced that the company expects to achieve operating revenue of 37.3253 million yuan for the fiscal year 

### [Healthcare Industry Daily (02.24): Pharmaceutical Industry Dynamics](https://longbridge.com/en/news/276777680.md)
*2026-02-24T19:13:16.000Z*
> Pfizer has reached a strategic cooperation with Xianweida Bio to obtain exclusive commercialization rights for the GLP-1

### [China Biopharmaceutical: The Phase III clinical trial of Vitreotide's "CLDN18.2 ADC" has completed subject enrollment](https://longbridge.com/en/news/275237589.md)
*2026-02-08T22:21:03.000Z*
> SINO BIOPHARM announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology, has completed patient enrollm

### [New Stock News | InventisBio plans to list on the Hong Kong Stock Exchange, and the China Securities Regulatory Commission requires supplementary explanations on compliance with safety production regulations](https://longbridge.com/en/news/275124493.md)
*2026-02-06T12:26:04.000Z*
> InventisBio plans to list on the Hong Kong stock market, but the China Securities Regulatory Commission requires it to p

### [Taiwan stocks rebounded strongly, benefiting from U.S. expansion and increased ETF allocations attracting investors' attention](https://longbridge.com/en/news/274801939.md)
*2026-02-04T11:20:03.000Z*
> Taiwan's stock market rebounded strongly, benefiting from the expansion of the U.S. market and increased ETF allocations

### [InventisBio expects a net loss of 292 million yuan for the fiscal year 2025](https://longbridge.com/en/news/274154090.md)
*2026-01-29T13:01:05.000Z*
> InventisBio announced an expected net loss of 292 million yuan for the annual performance in 2025. The performance chang

### [Zhitong A-share lock-up release overview | January 26](https://longbridge.com/en/news/273629287.md)
*2026-01-26T01:02:06.000Z*
> On January 26, a total of 8 listed companies will have their restricted shares unlocked, with a total market value of ap